Lenzetto (Estradiol Hemihydrate)

Lenzetto is an estrogen‑based therapy used to address conditions linked to low endogenous estrogen levels.

• Menopausal vasomotor symptoms: reduces frequency and severity of hot flashes and night sweats.
• Estrogen deficiency: restores hormonal balance and alleviates associated discomfort.
• Prevention of osteoporosis: helps maintain bone mineral density and reduces fracture risk in postmenopausal women.

• Estradiol binds to estrogen receptors ERα and ERβ in target tissues, initiating receptor dimerization and recruitment of co‑activators. This modulates gene transcription, leading to estrogenic effects such as regulation of the hypothalamic‑pituitary‑gonadal axis, promotion of bone formation, and stabilization of vascular endothelium, thereby correcting estrogen deficiency.

Adverse reactions may occur with any estrogen therapy.

Common Side Effects

• Skin irritation at the patch site: redness, itching, or rash.
• Headache: mild to moderate intensity.
• Breast tenderness: discomfort or swelling.
• Nausea: occasional upset stomach.
• Mood changes: irritability or mild depression.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Stroke or myocardial infarction: increased cardiovascular risk.
• Endometrial hyperplasia or carcinoma: abnormal uterine bleeding.
• Hepatic dysfunction: jaundice or elevated liver enzymes.
• Severe allergic reaction: anaphylaxis or angioedema.

Before initiating therapy, consider patient‑specific risk factors and monitor appropriately.

• Cardiovascular risk assessment: evaluate history of thrombosis, stroke, or myocardial infarction.
• Breast cancer surveillance: conduct regular examinations and imaging as indicated.
• Liver function monitoring: check hepatic enzymes periodically.
• Use lowest effective dose: adjust based on symptom control and side‑effect profile.
• Contraindicated in pregnancy: avoid use in women who are or may become pregnant.
• Store at room temperature: keep in original pouch, protect from light and moisture.

Estradiol may interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid)

• Combined estrogen‑progestin oral contraceptives: increased risk of venous thromboembolism.
• Warfarin: potentiation of anticoagulant effect, leading to bleeding.
• Tamoxifen: antagonistic action reducing therapeutic benefit.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): may raise estradiol plasma levels.
• CYP3A4 inducers (e.g., rifampin): may lower estradiol exposure.
• Selective serotonin reuptake inhibitors: can exacerbate hot flashes.